This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
New federal limits on state-directed payments are set to cut Medicaid funding in most states. Hospitals are expected to bear the brunt since they account for the majority—84%, around $78B a year—of state-directed healthcare spends.
Either the stakeholders issuing the warnings overstated the risk of widespread closings—or COVID-era emergency funds succeeded in heading off a calamity of national proportions. Either way, patient access has taken a hit here and there.
Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.
The Kentucky-based insurance giant had owned a 40% stake in the hospice company, stemming from its 2021 acquisition of Kindred Healthcare. Humana said a “consortium of investors" is making the buy, but few details were revealed.
CT-FFR, which recently got a boost from the 2021 AHA/ACC chest pain guidelines, could play a key role for clinicians hoping to screen TAVR patients for coronary heart disease.
As a result, the company stated it will pause the practice of prescribing controlled substances as a treatment for ADHD such as Adderall and Ritalin for new patients starting May 9.
The study's authors tracked data from six different randomized controlled trials, including a large study from 2021 that focused on myocardial infarction patients.
The 66-year-old cardiologist was first charged with sexual assault in 2022 after a patient accused him of touching her inappropriately. Now, more patients have stepped forward with similar stories.